The nod is subject to amendment in how primary efficacy endpoint for symptomatic cases be studied in Phase 3 trials, the panel further stated.
from Hindustan Times - india https://ift.tt/2HoFUiA
Home »
Hindustan Times - india
» Covaxin: Bharat Biotech gets nod from DCGI panel for Phase III trials
No comments:
Post a Comment